News

reMYND licenses highly innovative transgenic mouse models

20-08-2008
reMYND licenses highly innovative transgenic mouse models of Alzheimer's Disease TAU and Amyloid pathology from the University of Leuven. Visit the University of Leuven website

reMYND installs world-class scientific advisory board

25-06-2008
reMYND installs world-class scientific advisory board with Parkinson's and Alzheimer's Disease experts.

Lead product for treating Parkinson's Disease demonstrates efficacy

15-03-2008
Lead product for treating Parkinson's Disease demonstrates efficacy in 3 different animal models of Parkinson's Disease: a chemically-induced model and 2 different transgenic α-synuclein mouse models.

reMYND signs license agreement

20-12-2007
reMYND signs a license agreement with another biotech company for their internal use of reMYND’s proprietary APPLon model.

reMYND's Parkinson's disease drug discovery program reaches breakthrough

26-03-2007
Press release | reMYND nv announced today that it has reached a breakthrough in its drug discovery program aimed at identifying disease-modifying drugs for the treatment of Parkinson's disease.

Pages